Neurocrine Biosciences reported a 44% year-on-year revenue increase to $811 million in Q1 2026, fueled by strong sales of its drugs Ingrezza and Crenessity, as well as rapid growth from its recent acquisition, Vykat. The company’s stock valuation reflects high growth expectations, supported by patent protection through 2038 and a solid pipeline of new drug approvals. This positions Neurocrine for sustained long-term growth in the biotech sector.

More News (NBIX)

Neurocrine starts Phase 2 trial of CRENESSITY for young children with congenital adrenal hyperplasia.

Neurocrine Biosciences has launched a Phase 2 clinical trial to test the safety and tolerability of CRENESSITY (crinecerfont) in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH), a rare genetic disorder. CRENE...

Market News

Bullish

1 day ago

Neurocrine Biosciences posts 44% revenue growth in Q1 2026, driven by key drugs and new acquisition.

More News (NBIX)

Neurocrine starts Phase 2 trial of CRENESSITY for young children with congenital adrenal hyperplasia.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Neurocrine Biosciences posts 44% revenue growth in Q1 2026, driven by key drugs and new acquisition.

More News (NBIX)

Neurocrine starts Phase 2 trial of CRENESSITY for young children with congenital adrenal hyperplasia.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App